Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Growth/differentiation factor-15: prostate cancer suppressor or promoter?

P. Vaňhara, A. Hampl, A. Kozubík, K. Souček

. 2012 ; 15 (4) : 320-328.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc13031935

Grant support
NS9600 MZ0 CEP Register
NS9956 MZ0 CEP Register

Deregulation of expression and function of cytokines belonging to the transforming growth factor-β (TGF-β) family is often associated with various pathologies. For example, this cytokine family has been considered a promising target for cancer therapy. However, the detailed functions of several cytokines from the TGF-β family that could have a role in cancer progression and therapy remain unclear. One of these molecules is growth/differentiation factor-15 (GDF-15), a divergent member of the TGF-β family. This stress-induced cytokine has been proposed to possess immunomodulatory functions and its high expression is often associated with cancer progression, including prostate cancer (PCa). However, studies clearly demonstrating the mechanisms for signal transduction and functions in cell interaction, cancer progression and therapy are still lacking. New GDF-15 roles have recently been identified for modulating osteoclast differentiation and for therapy for PCa bone metastases. Moreover, GDF-15 is as an abundant cytokine in seminal plasma with immunosuppressive properties. We discuss studies that focus on the regulation of GDF-15 expression and its role in tissue homeostasis, repair and the immune response with an emphasis on the role in PCa development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031935
003      
CZ-PrNML
005      
20141113114321.0
007      
ta
008      
131002s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/pcan.2012.6 $2 doi
035    __
$a (PubMed)22370725
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vaňhara, P. $u Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Growth/differentiation factor-15: prostate cancer suppressor or promoter? / $c P. Vaňhara, A. Hampl, A. Kozubík, K. Souček
520    9_
$a Deregulation of expression and function of cytokines belonging to the transforming growth factor-β (TGF-β) family is often associated with various pathologies. For example, this cytokine family has been considered a promising target for cancer therapy. However, the detailed functions of several cytokines from the TGF-β family that could have a role in cancer progression and therapy remain unclear. One of these molecules is growth/differentiation factor-15 (GDF-15), a divergent member of the TGF-β family. This stress-induced cytokine has been proposed to possess immunomodulatory functions and its high expression is often associated with cancer progression, including prostate cancer (PCa). However, studies clearly demonstrating the mechanisms for signal transduction and functions in cell interaction, cancer progression and therapy are still lacking. New GDF-15 roles have recently been identified for modulating osteoclast differentiation and for therapy for PCa bone metastases. Moreover, GDF-15 is as an abundant cytokine in seminal plasma with immunosuppressive properties. We discuss studies that focus on the regulation of GDF-15 expression and its role in tissue homeostasis, repair and the immune response with an emphasis on the role in PCa development.
650    12
$a nádory kostí $x genetika $x metabolismus $x sekundární $7 D001859
650    _2
$a buněčná diferenciace $7 D002454
650    12
$a růstový diferenciační faktor 15 $x genetika $x metabolismus $7 D055436
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresivní léčba $7 D007165
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a osteoklasty $x cytologie $x metabolismus $7 D010010
650    12
$a nádory prostaty $x genetika $x metabolismus $7 D011471
650    _2
$a signální transdukce $7 D015398
650    _2
$a transformující růstový faktor beta $x metabolismus $7 D016212
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Hampl, A. $u Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Interantional Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Kozubík, A. $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Souček, K. $u Interantional Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
773    0_
$w MED00008064 $t Prostate cancer and prostatic diseases $x 1476-5608 $g Roč. 15, č. 4 (2012), s. 320-328
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22370725 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20141113114335 $b ABA008
999    __
$a ok $b bmc $g 996022 $s 830380
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 15 $c 4 $d 320-328 $i 1476-5608 $m Prostate cancer and prostatic diseases $n Prostate Cancer Prostatic Dis $x MED00008064
GRA    __
$a NS9600 $p MZ0
GRA    __
$a NS9956 $p MZ0
LZP    __
$a Pubmed-20131002
Back

Find record

Citation metrics

Archiving options